Liu described the CAR-like T cells as cytokine-activated lymphocytes engineered with the tumor-targeting and -penetrating ...

A new "double-pronged" CAR T immunotherapy recognizes two distinct features of multiple myeloma to destroy the cancer more ...

CAR T-cell therapy has revolutionized treatment for many blood cancers. However, the benefits of its use in the early stages of care remain uncertain. Chimeric antigen receptor (CAR) T-cell therapy ...

Chimeric antigen receptor (CAR) T cell therapy, which uses a patient's own immune cells to fight cancer, has emerged as a powerful way to treat lymphoma and other blood cancers. But researchers have ...

Chimeric antigen receptor (CAR) T-cell therapies have transformed cancer and autoimmune disease treatment. Modified CAR proteins equip T cells with the ability to identify and eliminate cancer cells ...

This review article highlights the transformative potential of in vivo CAR T cell therapy in addressing the limitations of traditional CAR T cell production. This innovative approach could ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...

Capstan Therapeutics scientists demonstrate that lipid nanoparticles can engineer CAR T cells within the body without laboratory cell manufacturing and ex vivo expansion. The method using targeted ...

Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...